Dowling Paul, Meleady Paula, Henry Michael, Clynes Martin
National Institute for Cellular Biotechnology (NICB), Dublin City University, Glasnevin, Dublin 9, Ireland.
Bioanalysis. 2010 Sep;2(9):1609-15. doi: 10.4155/bio.10.69.
The ultimate objective of clinical proteomics is the successful discovery, validation and translation of biomarkers, together with new therapeutic targets into medical practices. New highly developed technologies in proteomics and their use in understanding tumor biology have significant clinical potential in the diagnosis, prognosis and treatment of disease. Areas such as MS, new labeling technologies and advancements in bioinformatics systems are now used to successfully detect disease-associated biomarkers together with therapeutic targets in complex biological specimens, including biofluids, cell lysates and tissue biopsies. Recent improvements in sample preparation (specifically focused on fractionation and enrichment) are enabling the analysis of low-abundance proteins together with many types of post-translational modifications. Targeted proteomic diagnostics will play a significant role in the development of personalized molecular medicine, a process that will be vital in modernizing healthcare structures.
临床蛋白质组学的最终目标是成功发现、验证生物标志物以及新的治疗靶点，并将其转化应用于医疗实践。蛋白质组学中高度发达的新技术及其在理解肿瘤生物学方面的应用，在疾病的诊断、预后和治疗中具有巨大的临床潜力。诸如质谱分析、新的标记技术以及生物信息学系统的进展等领域，现在已被用于在包括生物流体、细胞裂解物和组织活检在内的复杂生物样本中成功检测与疾病相关的生物标志物以及治疗靶点。样本制备方面的最新改进（特别侧重于分级分离和富集）使得能够分析低丰度蛋白质以及多种类型的翻译后修饰。靶向蛋白质组学诊断将在个性化分子医学的发展中发挥重要作用，而这一过程对于实现医疗结构现代化至关重要。
